Therapeutic Bridge Between Pre- and Established Type 2 Diabetes
Glucobay® is the first-line approach to safe, long-term glycaemic control and cardiovascular risk reduction through a decrease in postprandial hyperglycaemia. Glucobay® also effectively and safely reduces the risk of developing type 2 diabetes by decreasing postprandial hyperglycaemia.

Postprandial hyperglycaemia plays a key part in progression of dysglycaemia throughout the disease continuum. Glucobay® directly reduces postprandial hyperglycaemia when taken with meals and can be used throughout the dysglycaemia disease continuum. The early use of Glucobay® at the prediabetes stage reduces the risk of developing type 2 diabetes.
 
The early use of Glucobay® at the prediabetes stage reduces the risk of developing type 2 diabetes.
Glucobay® signifcantly reduces the risk of CV complications in subjects with established type 2 diabetes.
Glucobay® is currently the only oral antidiabetes agent approved for prediabetes, based on proven clinical benefits.
Glucobay® has an excellent safety profile, is not associated with weight gain and is most efficacious when taken with healthy meals.
Glucobay® reduces the risk of developing diabetes to a similar extent as lifestyle modification, and this treatment is cost-effective.
Glucobay® is a suitable first-line pharmacotherapy for individuals at all stages of the dysglycaemia disease continuum.
 
 
Publications on the Benefit of Glucobay to Prevent Diabetes
Impaired glucose tolerance is a risk factor for progression to diabetes. Glucobay® delays the progression from impaired glucose tolerance to diabetes.
more
 
Publications on the Efficacy of Glucobay
Glucobay® is an effective first-line anti-diabetes agent. It is the most extensively investigated and widely prescribed alpha-glucosidase inhibitor and reduces all relevant glycemic parameters especially post prandial plasma glucose excursions by delaying the absorption of carbohydrate from the small intestine.
more
 
Acarbose - Understanding How it Works
To understand the therapeutic efficacy of Glucobay® it may be helpful for you to see this graphic animation of its pharmacological effect.
more
 
Important Treatment Recommendations
As in any other drug treatment, finding the adequate dosage and individual treatment regimen depends on your personal decision as a healthcare professional. However, additional advice may be benefitial for the overall treatment success and may contribute to an adequate patient compliance.
more
 
Prescribing Info of Glucobay
The dosage must be adjusted by the doctor to suit each patient, because efficacy and tolerance vary from one individual to another.
more
 
Summary of Product Characteristics
The summary of product characteristics (SPC) depicts all general information required for the prescription of Glucobay®.
more
 
International Availability of Glucobay
Glucobay® is approved in more than 95 countries and launched in more than 65 countries. Visit our local websites and learn more about Glucobay® in your language. Please note that product names may vary in different countries.
more
Glucobay® is already approved as a treatment for prediabetes in more than 20 countries. List of countries
Aruba
Bostwana
Brazil
China
Domincan Republic
Ecuador
El Salavador
Finland
Guatemala
Honduras
Hong Kong
India
Kenya
Mexico
Namibia
Nicaragua
Pakistan
Paraguay
Philippines
Portugal
South Africa
Thailand
Tanzania
Trinidad/Tobago
Turkey
Uganda
Venezuela

New Guidelines

The new ESC-EASD Guidelines on Diabetes, Prediabetes and Cardiovascular Diseases were presented at the implementation meeting in Nice end of June.
Click here to get to the webcast.

diabetes_symposium_153x62.gif

Scientific Papers

Reprints of articles relating to type 2 diabetes and its treatment with Glucobay®. more

Associated Risks

Hyperglycaemia is associated with risks

modul_3.gif

Lifestyle Modification

Lifestyle modification in individuals with prediabetes

modul_9.gif

Treatment

Initiation of drug treatment

modul_10.gif